Top of this page
Skip navigation, go straight to the content

Our Science Pipeline
 

PIPELINE

 

Our researchers, assisted by world class facilities and ground-breaking scientific platforms, are continually evolving and improving our science, their knowledge and capabilities. This has fueled a strong pipeline spanning several therapy areas that we are confident will deliver highly differentiated solutions.

MOLECULE
MODALITY
THERAPEUTIC AREA
INDICATION
PHASE
1 2 3 Filing
INFORMATION
Bimekizumab
  • Monoclonal antibody
    Immunology
    Psoriasis
    Filing
    Filing in the USA

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

  • Monoclonal antibody
    Immunology
    Psoriatic arthritis
    Phase 2.5
    Topline results end 2021

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

  • Monoclonal antibody
    Immunology
    Axial spondyloarthritis
    Phase 2.5
    Topline results end 2021

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

  • Monoclonal antibody
    Immunology
    Hidradenitis suppurativa
    Phase 2.5
    Topline results H2 2022

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

Zilucoplan
  • Macrocyclic peptide
    Neurology
    Myasthenia gravis
    Phase 2.5
    Topline results Q4 2021

    Zilucoplan is an investigational macrocyclic peptide inhibitor of complement component 5 (C5). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis.

    Zilucoplan is being investigated for the treatment of amyotrophic lateral sclerosis (ALS) as part of the HEALEY ALS Platform Trial.

Rozanolixizumab
  • Monoclonal antibody
    Immunology
    Myasthenia gravis
    Phase 2.5
    Topline results Q1 2022

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

  • Monoclonal antibody
    Immunology
    Immune thrombocytopenia
    Phase 2.5
    Topline results H2 2022

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

  • Monoclonal antibody
    Immunology
    Myelin oligodendrocyte glycoprotein (MOG) antibody disease
    Phase 2
    Phase 3 to start Q4 2021

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

  • Monoclonal antibody
    Immunology
    Autoimmune encephalitis
    Phase 1
    Phase 2 to start in Q3 2021 / topline results H1 2024

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

Dapirolizumab pegol
  • Monoclonal antibody
    Immunology
    Systemic lupus erythematosus
    Phase 2.5
    Topline results H1 2024

    Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease.

    Dapirolizumab pegol is being co-developed with Biogen.

Staccato® (alprazolam)
  • Small molecule
    Neurology
    Active epileptic seizure
    Phase 2
    Phase 3 to start Q4 2021

    Staccato® Alprazolam is an orally-inhaled investigational therapy designed to be used as a single-use epileptic seizure rescue therapy that combines the Staccato® delivery technology with alprazolam, a benzodiazepine.

Bepranemab
  • Monoclonal antibody
    Neurology
    Alzheimer's disease
    Phase 1.5
    Topline results H1 2025

    Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein.

    Bepranemab is being co-developed with Roche/Genentech.

UCB0599
  • Small molecule
    Neurology
    Parkinson's disease
    Phase 1.5
    Topline results H2 2023

    UCB0599 is an investigational small molecule that prevents the pathological misfolding and accumulation of alpha-synuclein, a protein which plays a role in Parkinson’s disease (PD) pathology. Inhibition of alpha-synuclein misfolding has the potential to slow down the progression of PD.

    UCB0599 belongs to a series of molecules discovered by Neuropore, which were in-licensed by UCB in 2014.